Neurogene (NGNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 9. Analyst Mani Foroohar from Leerink Partners reiterated a Buy rating on the stock and has a $72.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mani Foroohar has given his Buy rating due to a combination of factors including Neurogene’s strategic advancements in their clinical trials and a strong financial position. The company is making progress in its Phase 1/2 trial, enrolling additional patients in both pediatric and older cohorts, which is expected to provide valuable data updates in the second half of 2025. Additionally, Neurogene’s participation in the FDA’s START Pilot Program may offer further insights into regulatory decisions, potentially benefiting their trial design and execution.
Moreover, the financial health of Neurogene is robust, with cash reserves of $292.6 million, which are projected to support operations until the second half of 2027. This financial stability, coupled with the anticipated regulatory updates and trial advancements, contributes to a positive outlook for the company’s stock. Foroohar also notes that the market’s concerns about regulatory uncertainties may be overstated, given the clinically relevant metrics being pursued by Neurogene.